<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 09 Mar 2021 21:04:40 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>盘点：PD-1/PD-L1撤回的适应症</title><link>https://mp.weixin.qq.com/s/7ZyRcLx8pyOwXgJ8_X6ODQ</link><description></description><content:encoded><![CDATA[盘点：PD-1/PD-L1撤回的适应症]]></content:encoded><pubDate>Tue, 09 Mar 2021 19:37:16 +0800</pubDate></item><item><title>云南白药新CEO上任，来自华为！</title><link>https://mp.weixin.qq.com/s/IrVLR6-WarW9Cdn-9-hX7g</link><description></description><content:encoded><![CDATA[云南白药新CEO上任，来自华为！]]></content:encoded><pubDate>Tue, 09 Mar 2021 19:37:16 +0800</pubDate></item><item><title>和黄医药再启港交所IPO，呋喹替尼收入破2亿，两款新药将在美国NDA</title><link>https://mp.weixin.qq.com/s/vKInJ-wTFXQKhS0DToXG2g</link><description></description><content:encoded><![CDATA[和黄医药再启港交所IPO，呋喹替尼收入破2亿，两款新药将在美国NDA]]></content:encoded><pubDate>Tue, 09 Mar 2021 19:37:16 +0800</pubDate></item><item><title>新靶点IL-36R银屑病新药一项II期研究失败</title><link>https://mp.weixin.qq.com/s/BA1UoK_yErTY5uVpOmepkg</link><description></description><content:encoded><![CDATA[新靶点IL-36R银屑病新药一项II期研究失败]]></content:encoded><pubDate>Tue, 09 Mar 2021 19:37:16 +0800</pubDate></item><item><title>首仿！正大天晴「仑伐替尼胶囊」即将获批上市</title><link>https://mp.weixin.qq.com/s/jhntq5K0eT77zIlfXLivrQ</link><description></description><content:encoded><![CDATA[首仿！正大天晴「仑伐替尼胶囊」即将获批上市]]></content:encoded><pubDate>Mon, 08 Mar 2021 16:43:07 +0800</pubDate></item><item><title>2月肺癌月报 | 靶向ALK、MET突破连连，O药、Rova-T折戟SCLC又与何人说？</title><link>https://mp.weixin.qq.com/s/WN_Eeyku9u_bfp1Rm6CueA</link><description></description><content:encoded><![CDATA[2月肺癌月报 | 靶向ALK、MET突破连连，O药、Rova-T折戟SCLC又与何人说？]]></content:encoded><pubDate>Mon, 08 Mar 2021 16:43:07 +0800</pubDate></item><item><title>60%患者完全缓解！吉利德CAR-T疗法Yescarta第3项适应症获批</title><link>https://mp.weixin.qq.com/s/7dxwpyBAOQQid8I_AOvSfg</link><description></description><content:encoded><![CDATA[60%患者完全缓解！吉利德CAR-T疗法Yescarta第3项适应症获批]]></content:encoded><pubDate>Mon, 08 Mar 2021 16:43:07 +0800</pubDate></item><item><title>2020年全球热门靶点新药市场格局</title><link>https://mp.weixin.qq.com/s/ZLCoZRn77E-6ghLrcXGZoQ</link><description></description><content:encoded><![CDATA[2020年全球热门靶点新药市场格局]]></content:encoded><pubDate>Mon, 08 Mar 2021 16:43:07 +0800</pubDate></item><item><title>百济神州PD-1第6项适应症上市申请获受理，治疗NSCLC</title><link>https://mp.weixin.qq.com/s/t-c1xpp_t6mV_uvdi0SdRg</link><description></description><content:encoded><![CDATA[百济神州PD-1第6项适应症上市申请获受理，治疗NSCLC]]></content:encoded><pubDate>Sat, 06 Mar 2021 08:07:44 +0800</pubDate></item><item><title>优效于克唑替尼，FDA批准劳拉替尼一线治疗ALK阳性NSCLC</title><link>https://mp.weixin.qq.com/s/5mTbHPVo5rOJy1TQGQmCEA</link><description></description><content:encoded><![CDATA[优效于克唑替尼，FDA批准劳拉替尼一线治疗ALK阳性NSCLC]]></content:encoded><pubDate>Fri, 05 Mar 2021 17:51:49 +0800</pubDate></item><item><title>《政府工作报告》7大医药重点</title><link>https://mp.weixin.qq.com/s/XjArBZprmJxHS1KipmAkhw</link><description></description><content:encoded><![CDATA[《政府工作报告》7大医药重点]]></content:encoded><pubDate>Fri, 05 Mar 2021 17:51:49 +0800</pubDate></item><item><title>FDA批准儿童多动症新药上市</title><link>https://mp.weixin.qq.com/s/D9mnmnTv_Y6lYSUqJShLnQ</link><description></description><content:encoded><![CDATA[FDA批准儿童多动症新药上市]]></content:encoded><pubDate>Fri, 05 Mar 2021 17:51:49 +0800</pubDate></item><item><title>今日6款仿制药通过一致性评价，盐酸文拉法辛缓释胶囊首家过评</title><link>https://mp.weixin.qq.com/s/ymUCLy0UXdFcUQi8oy5xvA</link><description></description><content:encoded><![CDATA[今日6款仿制药通过一致性评价，盐酸文拉法辛缓释胶囊首家过评]]></content:encoded><pubDate>Fri, 05 Mar 2021 17:51:49 +0800</pubDate></item><item><title>君实生物高尿酸血症新药临床申请获受理</title><link>https://mp.weixin.qq.com/s/cNT6K8Y8Rp8r9mioD8RGTw</link><description></description><content:encoded><![CDATA[君实生物高尿酸血症新药临床申请获受理]]></content:encoded><pubDate>Fri, 05 Mar 2021 17:51:49 +0800</pubDate></item><item><title>治疗脱发！礼来JAK抑制剂 III 期研究成功</title><link>https://mp.weixin.qq.com/s/C1KBtrrrwAJLDA3i-DQolg</link><description></description><content:encoded><![CDATA[治疗脱发！礼来JAK抑制剂 III 期研究成功]]></content:encoded><pubDate>Thu, 04 Mar 2021 14:19:15 +0800</pubDate></item><item><title>最新！全球药企排名TOP10</title><link>https://mp.weixin.qq.com/s/kBGxQPr9wLLy_eErHeyjFA</link><description></description><content:encoded><![CDATA[最新！全球药企排名TOP10]]></content:encoded><pubDate>Thu, 04 Mar 2021 14:19:15 +0800</pubDate></item><item><title>葛兰素史克「多替拉韦拉米夫定片」在华获批上市！</title><link>https://mp.weixin.qq.com/s/kaBiB9YWRf23ZVCRIm2GQQ</link><description></description><content:encoded><![CDATA[葛兰素史克「多替拉韦拉米夫定片」在华获批上市！]]></content:encoded><pubDate>Thu, 04 Mar 2021 14:19:15 +0800</pubDate></item><item><title>贝达药业三代EGFR抑制剂申报上市，四代获批临床</title><link>https://mp.weixin.qq.com/s/JxAXlXe5P_iQHhThLkLrfg</link><description></description><content:encoded><![CDATA[贝达药业三代EGFR抑制剂申报上市，四代获批临床]]></content:encoded><pubDate>Thu, 04 Mar 2021 14:19:15 +0800</pubDate></item><item><title>首仿！恒瑞「托伐普坦片 」获批上市</title><link>https://mp.weixin.qq.com/s/uEJP1R-OK4LU0WKESkEUDg</link><description></description><content:encoded><![CDATA[首仿！恒瑞「托伐普坦片 」获批上市]]></content:encoded><pubDate>Thu, 04 Mar 2021 14:19:15 +0800</pubDate></item><item><title>君实向FDA滚动提交PD1单抗上市申请</title><link>https://mp.weixin.qq.com/s/Dpg9SDGuy3nhb_eeYniC4g</link><description></description><content:encoded><![CDATA[君实向FDA滚动提交PD1单抗上市申请]]></content:encoded><pubDate>Thu, 04 Mar 2021 14:19:15 +0800</pubDate></item></channel></rss>